BioMarin Closes Acquisition of Alesta Therapeutics
BioMarin Pharmaceutical completed its acquisition of Alesta Therapeutics, adding oral hypophosphatasia candidate ALE1; Alesta spun out all non-ALE1 assets before closing.
Read the full coverage, free
We only link to sources you can read without a subscription. How we check.